Clinical trial
RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post…
NCT00458367 · Janssen Pharmaceutica N.V., Belgium, Industry · Completed
Key facts
| NCT number | NCT00458367 |
|---|---|
| Title | RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice |
| Official title | Risperdal Safety Protocol Evaluation Consta Treatment; A Post Authorization Safety Survey With RISPERDAL CONSTA TM |
| Lead sponsor | Janssen Pharmaceutica N.V., Belgium, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Schizophrenia, Psychotic Disorders, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Open label risperidone long acting injectable |
| Enrollment | 5,296 |
| Start date | Jun 1, 2002 |
| Completion | Oct 1, 2006 |
| First posted | Apr 10, 2007 |
| Last update posted | Oct 18, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: